Author Archives: Patricia Inacio PhD

Immunotherapy Helps Myeloma Patients Who Relapse After Stem Cell Transplant, Study Shows

Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition usually associated with a poor prognosis. Dana-Farber Cancer Institute researchers tested the effects of a new treatment approach using repeated doses of the immunotherapy drug Yervoy (ipilimumab), showing…

One Multiple Myeloma Induction Therapy Stands Out in Test for Transplant-eligible Patients

Results from a clinical trial support the use of a specific combination drug induction therapy over another three-drug treatment in multiple myeloma patients who are eligible for transplants. The study indicates the combination of bortezomib-thalidomide-dexamethasone (VTD) is a better induction therapy than bortezomib-cyclophosphamide-dexamethasone (VCD). VCD was less efficient and was associated…